Advertisement

Tumor Biology

, Volume 31, Issue 5, pp 391–399 | Cite as

Quantitative analysis of BCL2 mRNA expression in nasopharyngeal carcinoma: an unfavorable and independent prognostic factor

  • Ali Fendri
  • Christos K. Kontos
  • Abdelmajid Khabir
  • Raja Mokdad-Gargouri
  • Alexandros Ardavanis
  • Andreas Scorilas
Research Article

Abstract

Programmed cell death plays a vital role in a wide variety of physiological processes. Defects in apoptotic cell death contribute to neoplastic diseases by preventing or delaying normal cell death. BCL2 (Bcl-2) is an anti-apoptotic gene with marked up-regulation in various malignancies, such as breast cancer, in which expression of the BCL2 protein has been proposed as a prognostic tumor biomarker. The purpose of the current study was to investigate mRNA expression of the BCL2 gene in nasopharyngeal carcinoma (NPC) biopsies and assess its prognostic value. For this purpose, total RNA was isolated from 89 malignant and hyperplastic nasopharyngeal biopsies from Tunisian patients. After testing the quality of the extracted RNA, cDNA was prepared by reverse transcription. A highly sensitive real-time PCR methodology for BCL2 mRNA quantification was developed using SYBR® Green chemistry. GAPDH served as an endogenous control gene. Relative quantification analysis was performed using the comparative C T (2−∆∆CT) method. High BCL2 mRNA levels were detected in advanced-stage nasopharyngeal tumors (p = 0.030). Furthermore, BCL2 mRNA expression was strongly associated with lymph node involvement (p = 0.009) and presence of distal metastases (p = 0.013). Survival analysis demonstrated that patients with BCL2-positive nasopharyngeal tumors have significantly shorter disease-free and overall survival (p = 0.011 and p = 0.028, respectively). The major contribution of the current study is the quantification and evaluation, for the first time, of the prognostic significance of the BCL2 mRNA expression in nasopharyngeal carcinoma (NPC) patients. Our results suggest that mRNA expression levels of BCL2 may represent a novel unfavorable and independent tumor biomarker for nasopharyngeal carcinoma.

Keywords

Apoptosis BCL2 (bcl-2Real-time PCR Tumor biomarkers Nasopharyngeal carcinoma (NPC) 

Notes

Acknowledgments

This work was supported by a Greek–Tunisian joint research and technology grant (EPAN.M.4.3.6.1 No 125-E), co-funded by the European Regional Development Funds (70% from the European Union), National Resources–Ministry of Development–General Secretariat for Research and Technology of Greece (30% from the governmental funds), and by the Biopaths Co.

References

  1. 1.
    Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239–57.PubMedGoogle Scholar
  2. 2.
    Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456–62.CrossRefPubMedGoogle Scholar
  3. 3.
    Thomadaki H, Scorilas A. Bcl2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci. 2006;43:1–67.CrossRefPubMedGoogle Scholar
  4. 4.
    Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999;17:2941–53.PubMedGoogle Scholar
  6. 6.
    Adams JM, Cory S. The bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Youle RJ, Strasser A. The bcl-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47–59.CrossRefPubMedGoogle Scholar
  8. 8.
    Petros AM, Olejniczak ET, Fesik SW. Structural biology of the bcl-2 family of proteins. Biochim Biophys Acta. 2004;1644:83–94.CrossRefPubMedGoogle Scholar
  9. 9.
    Korsmeyer SJ. Bcl-2 gene family and the regulation of programmed cell death. Cancer Res. 1999;59:1693s–700.PubMedGoogle Scholar
  10. 10.
    de Jong D, Prins FA, Mason DY, Reed JC, van Ommen GB, Kluin PM. Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res. 1994;54:256–60.PubMedGoogle Scholar
  11. 11.
    Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res. 1993;53:4701–14.PubMedGoogle Scholar
  12. 12.
    Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228:1440–3.CrossRefPubMedGoogle Scholar
  13. 13.
    Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cdnas for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 1986;47:19–28.CrossRefPubMedGoogle Scholar
  14. 14.
    Katsumata M, Siegel RM, Louie DC, Miyashita T, Tsujimoto Y, Nowell PC, et al. Differential effects of bcl-2 on t and b cells in transgenic mice. Proc Natl Acad Sci U S A. 1992;89:11376–80.CrossRefPubMedGoogle Scholar
  15. 15.
    Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell. 2003;3:17–22.CrossRefPubMedGoogle Scholar
  16. 16.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, et al. Prognostic significance of bcl-2 expression in stage iii breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer. 2007;7:63.CrossRefPubMedGoogle Scholar
  17. 17.
    Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C, et al. Role of bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2003;89:55–64.CrossRefPubMedGoogle Scholar
  18. 18.
    Sun SY, Yue P, Zhou JY, Wang Y, Choi Kim HR, Lotan R, et al. Overexpression of bcl2 blocks tnf-related apoptosis-inducing ligand (trail)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun. 2001;280:788–97.CrossRefPubMedGoogle Scholar
  19. 19.
    Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, et al. Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 1995;55:4471–8.PubMedGoogle Scholar
  20. 20.
    Gee JM, Robertson JF, Ellis IO, Willsher P, McClelland RA, Hoyle HB, et al. Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer. 1994;59:619–28.CrossRefPubMedGoogle Scholar
  21. 21.
    Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrjanen K. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol. 1995;177:49–55.CrossRefPubMedGoogle Scholar
  22. 22.
    Schorr K, Li M, Krajewski S, Reed JC, Furth PA. Bcl-2 gene family and related proteins in mammary gland involution and breast cancer. J Mammary Gland Biol Neoplasia. 1999;4:153–64.CrossRefPubMedGoogle Scholar
  23. 23.
    Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81:3091–6.PubMedGoogle Scholar
  24. 24.
    Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mrna as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol. 1998;9:159–65.CrossRefPubMedGoogle Scholar
  25. 25.
    Bairey O, Zimra Y, Shaklai M, Okon E, Rabizadeh E. Bcl-2, bcl-x, bax, and bak expression in short- and long-lived patients with diffuse large b-cell lymphomas. Clin Cancer Res. 1999;5:2860–6.PubMedGoogle Scholar
  26. 26.
    Nicholls JM, Agathanggelou A, Fung K, Zeng X, Niedobitek G. The association of squamous cell carcinomas of the nasopharynx with epstein-barr virus shows geographical variation reminiscent of Burkitt's lymphoma. J Pathol. 1997;183:164–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Busson P, Keryer C, Ooka T, Corbex M. Ebv-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends Microbiol. 2004;12:356–60.CrossRefPubMedGoogle Scholar
  28. 28.
    Khabir A, Sellami A, Sakka M, Ghorbel AM, Daoud J, Frikha M, et al. Contrasted frequencies of p53 accumulation in the two age groups of North African nasopharyngeal carcinomas. Clin Cancer Res. 2000;6:3932–6.PubMedGoogle Scholar
  29. 29.
    Daoud J, Toumi N, Bouaziz M, Ghorbel A, Jlidi R, Drira MM, et al. Nasopharyngeal carcinoma in childhood and adolescence: analysis of a series of 32 patients treated with combined chemotherapy and radiotherapy. Eur J Cancer. 2003;39:2349–54.CrossRefPubMedGoogle Scholar
  30. 30.
    Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomark Prev. 2006;15:1765–77.CrossRefGoogle Scholar
  31. 31.
    Feng BJ, Jalbout M, Ayoub WB, Khyatti M, Dahmoul S, Ayad M, et al. Dietary risk factors for nasopharyngeal carcinoma in Maghrebian countries. Int J Cancer. 2007;121:1550–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell. 2004;5:423–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.CrossRefPubMedGoogle Scholar
  34. 34.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta c(t)) method. Methods. 2001;25:402–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods. 2001;25:386–401.CrossRefPubMedGoogle Scholar
  36. 36.
    Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Cammoun M, Hoerner V, Mourali N. Tumors of the nasopharynx in Tunisia. An anatomic and clinical study based on 143 cases. Cancer. 1974;33:184–92.CrossRefPubMedGoogle Scholar
  38. 38.
    Van Houten N, Blake SF, Li EJ, Hallam TA, Chilton DG, Gourley WK, et al. Elevated expression of bcl-2 and bcl-x by intestinal intraepithelial lymphocytes: resistance to apoptosis by glucocorticoids and irradiation. Int Immunol. 1997;9:945–53.CrossRefPubMedGoogle Scholar
  39. 39.
    Friedman M, Grey P, Venkatesan TK, Bloch I, Chawla P, Caldarelli DD, et al. Prognostic significance of bcl-2 expression in localized squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 1997;106:445–50.PubMedGoogle Scholar
  40. 40.
    Gallo O, Bianchi S, Porfirio B. Bcl-2 overexpression and smoking history in head and neck cancer. J Natl Cancer Inst. 1995;87:1024–5.CrossRefPubMedGoogle Scholar
  41. 41.
    Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR, Begum S, et al. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2009;15:1645–54.CrossRefPubMedGoogle Scholar
  42. 42.
    Vera-Sempere FJ, Burgos JS, Botella MS, Morera C. Immunohistochemical expression of bcl-2 oncoprotein in EBV-associated nasopharyngeal carcinoma correlated to histological type and survival. Histol Histopathol. 1997;12:9–18.PubMedGoogle Scholar
  43. 43.
    Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer. 1995;71:1003–7.PubMedGoogle Scholar
  44. 44.
    Laudanski J, Chyczewski L, Niklinska WE, Kretowska M, Furman M, Sawicki B, et al. Expression of bcl-2 protein in non-small cell lung cancer: correlation with clinicopathology and patient survival. Neoplasma. 1999;46:25–30.PubMedGoogle Scholar
  45. 45.
    Binder C, Marx D, Overhoff R, Binder L, Schauer A, Hiddemann W. Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Ann Oncol. 1995;6:1005–10.PubMedGoogle Scholar
  46. 46.
    Sarac S, Akyol MU, Kanbur B, Poyraz A, Akyol G, Yilmaz T, et al. Bcl-2 and lmp1 expression in nasopharyngeal carcinomas. Am J Otolaryngol. 2001;22:377–82.CrossRefPubMedGoogle Scholar
  47. 47.
    Yu Y, Dong W, Li X, Yu E, Zhou X, Li S. Significance of c-myc and bcl-2 protein expression in nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:1322–6.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2010

Authors and Affiliations

  • Ali Fendri
    • 1
  • Christos K. Kontos
    • 2
  • Abdelmajid Khabir
    • 3
  • Raja Mokdad-Gargouri
    • 1
  • Alexandros Ardavanis
    • 4
  • Andreas Scorilas
    • 2
  1. 1.Unité de Recherche Génétique du Cancer et Production de protéines thérapeutiquesCentre de Biotechnologie de SfaxSfaxTunisia
  2. 2.Department of Biochemistry and Molecular Biology, Faculty of BiologyUniversity of AthensAthensGreece
  3. 3.Centre Hospitalo-Universitaire Habib BourguibaSfaxTunisia
  4. 4.First Department of Medical Oncology“Saint Savvas” Anticancer HospitalAthensGreece

Personalised recommendations